Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 87

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 87
---
, indirectly or constructively, at least 10% of the value or voting power of Innate's ordinary shares or ADSs, such U. S. holder may be treated as a “ United States shareholder” with respect to each “controlled foreign corporation” in its group, if any. Innate Pharma group currently includes one U. S. subsidiary and, therefore, under current law its current non-U. S. subsidiary and any future newly formed or acquired non-U. S. subsidiaries will be treated as controlled foreign corporations, regardless of whether the Company is treated as a controlled foreign corporation. A United States shareholder of a controlled foreign corporation may be required to annually report and include in its U. S. taxable income its pro rata share of “ Subpart F income,” “global intangible low-taxed income” and investments in U. S. property by controlled foreign corporations, regardless of whether Innate makes any distributions. An individual that is a U. S. shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U. S. shareholder that is a U. S. corporation. Failure to comply with controlled foreign corporation reporting obligations may subject a U. S. shareholder to significant monetary penalties. The Company cannot provide any assurances that it will furnish to any U. S. shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the controlled foreign corporation rules of the Code. U. S. holders should consult their tax advisors regarding the potential application of these rules to their investment in Innate's ordinary shares or ADSs.

Item 4. Information on the Company.